GlobeNewswire by notified

Valberedning inför Industrivärdens årsstämma 2021

Dela

Enligt det beslut om valberedningen som fattades vid årsstämman 2011, och som gäller tillsvidare, uppdras åt styrelsens ordförande att ta kontakt med fyra bland de röstmässigt största ägarregistrerade aktieägarna i Euroclear Sweden AB:s utskrift av aktieboken per sista bankdagen i augusti, som vardera utser en representant som inte är ledamot i bolagets styrelse att jämte ordföranden utgöra valberedning för ti-den intill dess att ny valberedning utsetts. Valberedningen utser ordföranden inom gruppen. Sammansättningen av valberedningen ska tillkännages senast sex månader före nästa årsstämma. Inget arvode ska utgå.

I enlighet härmed har valberedningen följande sammansättning: Mats Guldbrand, L E Lundbergföretagen, Stefan Nilsson, Handelsbankens Pensionsstiftelse m fl, Mikael Schmidt, SCA och Essity Pensionsstiftelser m fl, Bo Damberg, Jan Wallanders och Tom Hedelius stiftelse m fl samt Fredrik Lundberg, styrelseordförande i Industrivärden.

Om ledamot lämnar valberedningen innan dess arbete är slutfört, och om valbered-ningen anser att det finns behov av att ersätta denna ledamot, ska valberedningen utse ny ledamot. Ändring i valberedningens sammansättning ska offentliggöras omedelbart.

Årsstämma i Industrivärden kommer att hållas den 21 april 2021, klockan 14:00, i Vinterträdgården på Grand Hôtel i Stockholm.     


Stockholm den 25 september 2020

AB INDUSTRIVÄRDEN (publ)


För ytterligare information kontakta:

Fredrik Lundberg, Sammankallande i valberedningen, tel 08-463 06 00.


Informationen lämnades genom kommunikationschefen Sverker Sivalls (tel. 08-666 64 00) försorg, för offentliggörande den 25 september 2020 kl.10:00 CET.

Bilaga

För att se det här innehållet från www.globenewswire.com måste du ge ditt medgivande sidans topp.

Om

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Följ GlobeNewswire by notified

Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.

Senaste pressmeddelandena från GlobeNewswire by notified

Intervest Offices & Warehouses NV: Press release – Persbericht – Communiqué de presse: openbaarmaking over transparantiekennisgeving19.4.2024 18:00:00 CEST | Press release

Geachte mevrouw, meneer, Gelieve hierbij de links te vinden naar het recente persbericht van Intervest Offices & Warehouses betreffende de openbaarmaking over transparantiekennisgeving. Dear Madam, Sir, Please find hereunder the links to Intervest Offices & Warehouses’ latest press release regarding the publication of a transparency notification. Attachment NL_transparency notification_20240419

23/2024・Trifork Group AG – Shareholders approve all resolutions at the Annual General Meeting 202419.4.2024 17:34:19 CEST | Press release

Company announcement no. 23 / 2024 Schindellegi, Switzerland – 19 April 2024 Shareholders approve all resolutions at the Annual General Meeting 2024 The shareholders of Trifork Group AG (“Trifork“) today approved all resolutions proposed by the Board of Directors at Trifork’s Annual General Meeting 2024 (the “AGM“) which was held at Grabenstrasse 2, 6430 Baar, Switzerland. Dividend payment The shareholders approved the Board of Directors’ proposal to pay a gross dividend of EUR 0.10 per share (equivalent to CHF 0.10 per share) by making a payout from capital contribution reserves to the shareholders. The total gross dividend paid out amounts to CHFk 1,932, equivalent to DKKk 14,809, as calculated per the exchange rate published by the Swiss Federal Customs Administration as of 19 April 2024. The payout from capital contribution reserves is declared in CHF and paid out in DKK. Composition of the Board of Directors The shareholders re-elected Julie Galbo as Chairperson of the Board of Di

Havila Shipping ASA: Årsrapport 202319.4.2024 17:06:25 CEST | Pressemelding

Styret i Havila Shipping ASA har i dag godkjent regnskap og årsrapport for 2023 for konsern og morselskap. Resultatregnskap og balanser er i samsvar med foreløpig regnskap offentliggjort 27. februar 2024. Kontakter: Administrerende direktør Njål Sævik, +47 909 35 722 Finansdirektør Arne Johan Dale, +47 909 87 706 Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12 Vedlegg HAVI-20235967007LIEEXZXFJ8876-2023-12-31-no

Havila Shipping ASA : Annual Report 202319.4.2024 17:06:25 CEST | Press release

Today, the Board of Directors of Havila Shipping ASA has approved the financial statements for 2023 for both the Group and the parent company. The accounts are in line with preliminary accounts released on 27 February 2024. Contacts: Chief Executive Officer Njål Sævik, +47 909 35 722 Chief Financial Officer Arne Johan Dale, +47 909 87 706 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachments HAVI-20235967007LIEEXZXFJ8876-2023-12-31-no

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons19.4.2024 17:05:00 CEST | Press release

Company announcement – No. 23 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, April 19, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions. Please see the attached file(s). # # # About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and

HiddenA line styled icon from Orion Icon Library.Eye